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Clinics and pathology 
Disease 
Non Hodgkin lymphoma 
Clinics 
Only 3 cases to date of t(3;7)(q27;q32): a B-cell 
lymphoma cell line established from a 55-year-old 
male patient with terminal diffuse large B-cell 
lymphoma (DLBCL), a t(11;14)(q23;q32) and a 
complex karyotype (Schneider et al., 2008); a 54-year-
old male patient with stade IV splenic marginal zone B-
cell lymphoma (SMZL) and a complex karyotype with 
+3 who's survival was 9 years+ (Boonstra et al., 2003); 
and a female patient with stade IV SMZL and a 
complex karyotype (Ott et al., 2000). 
Genetics 
Note 
The molecular event involving FRA7H and BCL6 has 
been uncovered only in the most recent report 
(Schneider et al., 2008). 





706 amino acids; composed of a NH2-term BTB/POZ 
domain (amino acids 1-130 (32-99 according to Swiss-
Prot) which mediates  
homodimerization and protein-protein interactions with 
other corepressors (including HDAC1 and 
NCOR2/SMRT to constitute a large repressing 
complex, another transcription repression domain (191- 
386), PEST sequences (300-417) with a KKYK motif 
(375-379), and six zinc finger at the C-term (518-541, 
546-568, 574-596, 602-624, 630-652, 658-681), 
responsible for sequence specific DNA binding.  
Transcription repressor; recognizes the consensus 
sequence: TTCCT(A/C)GAA (Albagli-Curiel, 2003). 
Role in germinal centers of lymphoid follicles. BCL6 
prevents ATM and TP53 to induce apoptosis in 
response to DNA rearrangements such as somatic 
hypermutation and class switch recombination.  





Fragile site, aphidicolin type, common. 




The breakpoint at 7q32 maps within FRA7H; the 
breakpoint on chromosome 3 lies upstream of exon 1, 
out of both the major breakpoint region (MBR) and the
alternative breakpoint regions (ABR). Hence, BCL6 is 
constitutively, albeit moderately, expressed (Schneider 
et al., 2008). 
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